Latest Key Developments (Source: Significant Developments)

July 8 (Reuters) - Morphosys AG ::DGAP-NEWS: MORPHOSYS AND VIVORYON THERAPEUTICS ENTER AGREEMENT ON SMALL MOLECULE INHIBITORS OF CD47-SIRP ALPHA SIGNALING IN IMMUNO-ONCOLOGY.MORPHOSYS-IN EXCHANGE,CO COMMITTED TO INVESTING UP TO EUR 15 MILLION IN MINORITY STAKE IN VIVORYON AS PART OF A CAPITAL RAISE PLANNED FOR LATER THIS YEAR.MORPHOSYS -CO & VIVORYON THERAPEUTICS ENTERED DEAL UNDER WHICH CO OBTAINED EXCLUSIVE OPTION TO LICENSE VIVORYON'S SMALL MOLECULE QPCTL INHIBITORS IN FIELD OF ONCOLOGY.MORPHOSYS WILL CONDUCT PRECLINICAL VALIDATION EXPERIMENTS ON VIVORYON'S FAMILY OF QPCTL INHIBITORS.MORPHOSYS - IF CO CHOOSES TO EXERCISE OPTION, VIVORYON THERAPEUTICS WILL RECEIVE AN OPTION FEE, AND IS ELIGIBLE FOR MILESTONE PAYMENTS AND ROYALTIES.
Full Article

June 24 (Reuters) - MorphoSys AG ::DGAP-ADHOC: AD HOC: MORPHOSYS APPOINTS JEAN-PAUL KRESS, M.D., AS NEW CHIEF EXECUTIVE OFFICER.APPOINTMENT WILL TAKE EFFECT ON SEPTEMBER 1, 2019.APPOINTMENT NEW CHIEF EXECUTIVE OFFICER WILL TAKE EFFECT ON SEPTEMBER 1, 2019.MORPHOSYS - KRESS WILL SUCCEED DR. SIMON MORONEY, WHO HAD ANNOUNCED HIS DECISION NOT TO RENEW HIS CONTRACT AS A MEMBER OF MORPHOSYS'S MANAGEMENT BOARD.
Full Article

June 22 (Reuters) - MorphoSys AG ::MORPHOSYS PRESENTS PRIMARY ANALYSIS DATA FROM L-MIND STUDY OF TAFASITAMAB (MOR208) IN COMBINATION WITH LENALIDOMIDE IN R/R DLBCL AT ICML 2019.PRIMARY ENDPOINT HAS BEEN MET IN STUDY.L-MIND TREATMENT COMBINATION WAS GENERALLY WELL TOLERATED IN STUDY.ORR WAS 60% (48 OUT OF 80 PATIENTS), AND COMPLETE RESPONSE (CR) RATE WAS 43%.
Full Article

June 14 (Reuters) - MORPHOSYS AG ::MORPHOSYS'S LICENSEE JANSSEN ANNOUNCES TOP-LINE PHASE 3 RESULTS FOR GUSELKUMAB (TREMFYA(R)) IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS.ACCORDING TO JANSSEN, BOTH STUDIES MET THEIR PRIMARY ENDPOINTS.DATA WILL SERVE AS BASIS OF SUBMISSIONS FOR APPROVAL OF GUSELKUMAB AS A TREATMENT FOR PSORIATIC ARTHRITIS, WHICH ARE ANTICIPATED FOR LATER THIS YEAR.
Full Article

May 7 (Reuters) - MorphoSys AG ::SAYS MOR208: ROLLING SUBMISSION OF L-MIND STUDY DATA TO FDA TO SUPPORT POTENTIAL APPROVAL IN U.S. ON TRACK.SAYS DAVID TREXLER HIRED AS PRESIDENT, MORPHOSYS US INC.; BUILD-UP OF COMMERCIAL CAPABILITIES ONGOING.SAYS MOR208: INTERACTIONS WITH EUROPEAN REGULATORY AUTHORITIES TO EXPLORE USE OF L-MIND AS BASIS FOR A SUBMISSION OF A POTENTIAL MARKETING AUTHORIZATION APPLICATION IN EUROPE ONGOING.SAYS MOR202: PIVOTAL PHASE 2 STUDY IN THIRD LINE AND PHASE 3 STUDY IN SECOND LINE MULTIPLE MYELOMA STARTED BY PARTNER I-MAB IN TAIWAN.SAYS TREMFYA(R): CLINICAL DEVELOPMENT EXPANDED TO INCLUDE ULCERATIVE COLITIS (UC) AND FAMILIAL ADENOMATOUS POLYPOSIS (FAP).SAYS MOR106: START OF PHASE 2 GECKO TRIAL WITH MOR106 AND TOPICAL CORTICOSTEROIDS UNDER AGREEMENT WITH NOVARTIS.SAYS FINANCIAL GUIDANCE FOR 2019 REAFFIRMED.SAYS GROUP REVENUES ROSE TO EUR 13.5 MILLION, COMPARED TO EUR 2.8 MILLION IN Q1 OF 2018.SAYS EARNINGS BEFORE INTEREST AND TAXES (EBIT) AMOUNTED TO EUR -23.6 MILLION IN Q1 OF 2019 (Q1 2018: EUR -19.0 MILLION.SAYS IN Q1 2019, CONSOLIDATED NET LOSS AMOUNTED TO EUR -22.7 MILLION (Q1 2018: EUR -19.5 MILLION). LOSS PER SHARE FOR Q1 OF 2019 WAS EUR -0.72 (Q1 2018: EUR -0.67).
Full Article

April 24 (Reuters) - GALAPAGOS NV ::ANNOUNCED ON TUESDAY INITIATION OF GECKO.GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.RECRUITMENT WILL TAKE PLACE IN THE U.S. AND CANADA.STUDY IS INTENDED TO SERVE AS AN IND (INVESTIGATIONAL NEW DRUG) OPENER WITH THE U.S. FDA.
Full Article

Feb 19 (Reuters) - MorphoSys AG ::SIMON MORONEY, CEO AND CO-FOUNDER OF MORPHOSYS, ANNOUNCES HIS INTENTION TO RETIRE.MORONEY WILL STEP DOWN AS CEO ON EXPIRY OF HIS CURRENT CONTRACT ON JUNE 30, 2020, OR WHEN A SUCCESSOR IS APPOINTED, WHICHEVER COMES SOONER.
Full Article

Feb 5 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES APPOINTMENT OF DAVID TREXLER AS PRESIDENT AND MEMBER OF THE BOARD OF DIRECTORS OF MORPHOSYS US INC..MORPHOSYS AG SAYS APPOINTMENT OF DAVID R. TREXLER AS PRESIDENT AND MEMBER OF BOARD OF DIRECTORS OF MORPHOSYS US INC., EFFECTIVE FEBRUARY 6, 2019.
Full Article

Nov 5 (Reuters) - MorphoSys AG ::MORPHOSYS AG ANNOUNCES THIRD QUARTER 2018 RESULTS.Q3 REVENUE 55 MILLION EUR VERSUS 15 MILLION EUR YEAR AGO.CASH POSITION OF EUR 481.2 MILLION AS OF SEPTEMBER 30, 2018.CONFIRMS ITS 2018 FINANCIAL GUIDANCE WHICH HAD BEEN INCREASED AFTER SIGNING AN AGREEMENT WITH NOVARTIS FOR MOR106 IN JULY 2018.MORPHOSYS EXPECTS REVENUES ON UPPER END OF GUIDED RANGE FROM EUR 67 MILLION TO EUR 72 MILLION FOR 2018.
Full Article

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: